With Blackstone’s $300m, Uniquity Will Take On Tezspire In Respiratory Disease

Built around a TSLP-targeted antibody licensed from Merck, Uniquity begins with $300m from Blackstone to fund Phase II in asthma and COPD. But other anti-TSLP competition looms.